Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171919275> ?p ?o ?g. }
- W2171919275 endingPage "4774" @default.
- W2171919275 startingPage "4764" @default.
- W2171919275 abstract "Aurora A kinase (AAK) is a key regulator of mitosis and a target for anticancer drug development. This phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of MLN8237 (alisertib), an investigational, oral, selective AAK inhibitor, in 59 adults with advanced solid tumors.Patients received MLN8237 once daily or twice daily for 7, 14, or 21 consecutive days, followed by 14 days recovery, in 21-, 28-, or 35-day cycles. Dose-limiting toxicities (DLT) and the maximum-tolerated dose (MTD) for the 7- and 21-day schedules were determined. Pharmacokinetic parameters were derived from plasma concentration-time profiles. AAK inhibition in skin and tumor biopsies was evaluated and antitumor activity assessed.Neutropenia and stomatitis were the most common DLTs. The MTD for the 7- and 21-day schedules was 50 mg twice daily and 50 mg once daily, respectively. MLN8237 absorption was fast (median time to maximum concentration, 2 hours). Mean terminal half-life was approximately 19 hours. At steady state, pharmacodynamic effects were shown by accumulation of mitotic and apoptotic cells in skin, and exposure-related increases in numbers of mitotic cells with characteristic spindle and chromosomal abnormalities in tumor specimens, supporting AAK inhibition by MLN8237. Stable disease was observed and was durable with repeat treatment cycles, administered over 6 months, in 6 patients, without notable cumulative toxicity.The recommended phase II dose of MLN8237 is 50 mg twice daily on the 7-day schedule, which is being evaluated further in a variety of malignancies, including in a phase III trial in peripheral T-cell lymphoma." @default.
- W2171919275 created "2016-06-24" @default.
- W2171919275 creator A5011012477 @default.
- W2171919275 creator A5015190461 @default.
- W2171919275 creator A5016108968 @default.
- W2171919275 creator A5033071360 @default.
- W2171919275 creator A5035389997 @default.
- W2171919275 creator A5044490765 @default.
- W2171919275 creator A5049677294 @default.
- W2171919275 creator A5053953098 @default.
- W2171919275 creator A5055862157 @default.
- W2171919275 creator A5062635658 @default.
- W2171919275 creator A5069485042 @default.
- W2171919275 creator A5069781389 @default.
- W2171919275 creator A5082191671 @default.
- W2171919275 creator A5083582948 @default.
- W2171919275 creator A5088030098 @default.
- W2171919275 creator A5089989134 @default.
- W2171919275 creator A5091727687 @default.
- W2171919275 date "2012-08-30" @default.
- W2171919275 modified "2023-10-17" @default.
- W2171919275 title "Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors" @default.
- W2171919275 cites W1657157395 @default.
- W2171919275 cites W1886278373 @default.
- W2171919275 cites W1965478253 @default.
- W2171919275 cites W1970815499 @default.
- W2171919275 cites W1979795699 @default.
- W2171919275 cites W1980612591 @default.
- W2171919275 cites W1981073960 @default.
- W2171919275 cites W1985338536 @default.
- W2171919275 cites W1997353566 @default.
- W2171919275 cites W1998678044 @default.
- W2171919275 cites W2007608739 @default.
- W2171919275 cites W2008609502 @default.
- W2171919275 cites W2016462887 @default.
- W2171919275 cites W2027741380 @default.
- W2171919275 cites W2031805729 @default.
- W2171919275 cites W2048097747 @default.
- W2171919275 cites W2054464733 @default.
- W2171919275 cites W2061252160 @default.
- W2171919275 cites W2064261028 @default.
- W2171919275 cites W2066906356 @default.
- W2171919275 cites W2067115862 @default.
- W2171919275 cites W2068073581 @default.
- W2171919275 cites W2069910776 @default.
- W2171919275 cites W2072015866 @default.
- W2171919275 cites W2077212219 @default.
- W2171919275 cites W2079788104 @default.
- W2171919275 cites W2085227881 @default.
- W2171919275 cites W2095523826 @default.
- W2171919275 cites W2098845689 @default.
- W2171919275 cites W2115891953 @default.
- W2171919275 cites W2116565287 @default.
- W2171919275 cites W2119974970 @default.
- W2171919275 cites W2126572395 @default.
- W2171919275 cites W2127621535 @default.
- W2171919275 cites W2137429755 @default.
- W2171919275 cites W2139248078 @default.
- W2171919275 cites W2140029079 @default.
- W2171919275 cites W2144977250 @default.
- W2171919275 cites W2148375003 @default.
- W2171919275 cites W2150548655 @default.
- W2171919275 cites W2153081604 @default.
- W2171919275 cites W2241093797 @default.
- W2171919275 cites W2276913308 @default.
- W2171919275 cites W2553899159 @default.
- W2171919275 cites W3145531923 @default.
- W2171919275 cites W4250215301 @default.
- W2171919275 doi "https://doi.org/10.1158/1078-0432.ccr-12-0571" @default.
- W2171919275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22753585" @default.
- W2171919275 hasPublicationYear "2012" @default.
- W2171919275 type Work @default.
- W2171919275 sameAs 2171919275 @default.
- W2171919275 citedByCount "133" @default.
- W2171919275 countsByYear W21719192752012 @default.
- W2171919275 countsByYear W21719192752013 @default.
- W2171919275 countsByYear W21719192752014 @default.
- W2171919275 countsByYear W21719192752015 @default.
- W2171919275 countsByYear W21719192752016 @default.
- W2171919275 countsByYear W21719192752017 @default.
- W2171919275 countsByYear W21719192752018 @default.
- W2171919275 countsByYear W21719192752019 @default.
- W2171919275 countsByYear W21719192752020 @default.
- W2171919275 countsByYear W21719192752021 @default.
- W2171919275 countsByYear W21719192752022 @default.
- W2171919275 countsByYear W21719192752023 @default.
- W2171919275 crossrefType "journal-article" @default.
- W2171919275 hasAuthorship W2171919275A5011012477 @default.
- W2171919275 hasAuthorship W2171919275A5015190461 @default.
- W2171919275 hasAuthorship W2171919275A5016108968 @default.
- W2171919275 hasAuthorship W2171919275A5033071360 @default.
- W2171919275 hasAuthorship W2171919275A5035389997 @default.
- W2171919275 hasAuthorship W2171919275A5044490765 @default.
- W2171919275 hasAuthorship W2171919275A5049677294 @default.
- W2171919275 hasAuthorship W2171919275A5053953098 @default.
- W2171919275 hasAuthorship W2171919275A5055862157 @default.
- W2171919275 hasAuthorship W2171919275A5062635658 @default.
- W2171919275 hasAuthorship W2171919275A5069485042 @default.